Idorsia Pharmaceuticals Ltd
イドルシア・ファーマシューティカルズLtd.AliasIdorsiaAliasIdorsiaAlias
§01
Basic information
- Head office
- Allschwil, Switzerland
- Chief executive
- Employees (non-consolidated)
- Employees (consolidated)
- Start date
- End date
§02
Websites
§03
Business
QUVIVIQTRYVIO/JERAYGODrug discovery and research & developmentLucerastatSelatogrelCenerimodCCR6 antagonistCXCR7 antagonistCXCR3 antagonistCenerimod for systemic lupus erythematosus and lupus nephritisSelatogrel for acute myocardial infarctionLucerastat for Fabry diseaseIDOR-1117-2520 First-in-class selective CCR6 receptor antagonist psoriasisContinued QUVIVIQ sales growthCCR6 receptor antagonistCXCR7 antagonist for progressive MSCXCR3 receptor antagonist for vitiligodrug discoverydevelopmentregistrationproductionresearchclinical developmentcommercial operationsmarketing operationsresearch and development
§04
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
| Idorsia (Berlin) Pharmaceuticals GmbH | ||||||||
| Berlin-Chemie |
Names without a link are companies not yet registered in OpenBizGraph
§05
Network
Capital
Customer
Supplier
Partnership
Bank / shareholder
Drag to move · click to open
§07
News
There is no news.
§09
Sources & updates
DOMAINOwn domain：Yes
UPDATED2026-10-13 14:27 · Model: GPT-6 Luna